Abivax
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases....
Latest News
14 days ago · globenewswire.com
Abivax to Participate in Upcoming Fall Investor ConferencesAbivax to Participate in Upcoming Fall Investor Conferences PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences: Guggenheim Healthcare Innovation Conference Boston, MassachusettsNovember 9-11, 2026Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET LifeSci Capital X Sofinnova Growth & Innovation Summit London, United KingdomNovember 16, 2026 30 th German Equity Forum (Deutsches Eigenkapitalforum) Frankfurt, GermanyNovember 23-25, 2026Corporate Presentation: Monday, November 23r d, 11:40am-12:10pm CET Evercore ISI 9 th Annual Healthcare Conference Miami, FloridaNovember 30 – December 2, 2026Fireside Chat: Wednesday, December 2nd, 7:55-8:15am ET Piper Sandler 38 th Annual Healthcare Conference New York, New YorkDecember 1-3, 2026Fireside Chat: Thursday, December 3rd, 8:00-8:25am ET Webcast links for select presentations will be available in the Investors section of Abivax's website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company's website for a limited time following the conference.
1 month ago · seekingalpha.com
Cedar Grove Capital Q3 2026 Portfolio UpdateDuring the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Group, Gemini Space Station, Jersey Mike's Subs, Moderna, Reformation, Once Upon a Farm, and X-Energy Inc. We initiated a small tracking position in Zedcor Inc. while continuing our due diligence.
2 months ago · seekingalpha.com
Abivax: Priced Right Ahead Of 2 Make-Or-Break CatalystsAbivax Société Anonyme is advancing obefazimod for ulcerative colitis and Crohn's, with recent safety concerns now largely addressed. ABVX raised $920 million, extending its cash runway into Q4 2029 and strengthening its negotiating position for potential M&A. ABVX stock is fairly valued in the $90s, with upside contingent on a favorable UC label and positive Phase 2b CD data in 2027.
2 months ago · benzinga.com
These Analysts Slash Their Forecasts On Abivax Following H1 ResultsAbivax SA (NASDAQ:ABVX) reported mixed results for the first half of the year on Monday.
2 months ago · globenewswire.com
Abivax Presents Business Updates and First Half 2026 Financial ResultsAbivax Presents Business Updates and First Half 2026 Financial Results Chris Rabbat to succeed Fabio Cataldi as Chief Medical Officer; Tim Kelly appointed Chief Technical Officer to advance commercial supply readiness and lead Abivax's Chemistry, Manufacturing and Controls (“CMC”), Quality and Information Technology (“IT”) functions Cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026, combined with €767.1 million in net proceeds from the early July underwritten public offering, provides cash runway into Q4 2029 Royalty certificates buy-back completed in Q2 2026 materially reduces royalty overhang, further strengthening Abivax's debt-free financial position and flexibility to support future commercialization efforts PARIS, France – September 21, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, reported today business updates and financial results for the six months ended June 30, 2026. The half-year financial statements, approved by the Company's Board of Directors on September 18, 2026, have been reviewed by the Company's statutory auditors, and the financial reports will be filed with the French and U.S. securities regulatory authorities on September 21, 2026.
2 months ago · benzinga.com
Accenture, Abivax and 3 Stocks to Watch Heading Into MondayWith U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
2 months ago · zacks.com
4 Biotech Stocks to Watch as Potential Takeover TargetsBiotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
2 months ago · benzinga.com
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallABIVAX Société Anonyme (NASDAQ:ABVX) will release its first-half earnings report after the closing bell on Monday, Sept. 21.
2 months ago · zacks.com
Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's WhyAbivax SA Sponsored ADR (ABVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 months ago · seekingalpha.com
Abivax: Obefazimod Goes The Distance And So Does My Buy RatingAbivax (ABVX) maintains a Buy rating, supported by robust Phase 3 maintenance data for obefazimod in ulcerative colitis. ABVX demonstrated clinical remission rates of 50.8%–51.3% at week 44, with strong secondary endpoints and a favorable safety profile. A recent $920M capital raise funds operations into Q4 2029, enabling standalone commercialization and strengthening strategic positioning.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ABVX